MIAMI — For patients with idiopathic intracranial hypertension, GLP-1 receptor agonists may help with weight loss and play a role in reducing intracranial pressure, according to a speaker at Sunshine Eye & Retina.During a presentation, Julie Falardeau,…
Identify early dysfunction to preserve retinal reserve
Many retinal diseases begin long before patients experience noticeable vision loss.Clinicians frequently manage patients with early age-related macular degeneration, diabetes or glaucoma who maintain normal visual function despite underlying disease pr…
FDA loosens regulatory oversight for digital health innovation
LOS ANGELES — It is important for primary care providers to understand new federal regulations surrounding wearables, wellness and clinical decision support, especially because it will impact reimbursement, according to a speaker here.Aubrey Shick, a f…
Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
BENGALURU, India–(BUSINESS WIRE)–Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination &…
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics publie ses résultats financiers consolidés estimés pour l’année 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodé…